

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



DOCMODE HEALTH TECHNOLOGIES LIMITED

CIN: U74999MH2017PLC297413

Our Company was incorporated in Mumbai, Maharashtra, as a "Docmode Health Technologies Private Limited", a private limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated July 17, 2017 issued by the Deputy Registrar of Companies, Central Registration Centre. Thereafter, our Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by our Shareholders at the Extraordinary General Meeting held on December 15, 2022, and consequent upon conversion, the name of our Company was changed to "Docmode Health Technologies Limited" and a fresh certificate of incorporation dated January 2, 2023 bearing Corporate Identity Number U74999MH2017PLC297413 issued by Registrar of Companies, Maharashtra, Mumbai. For further details, please refer to the chapter titled "History and Certain Corporate Matters" beginning on page 143 of the Prospectus.

Registered Office: 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad Mumbai, -400064, Maharashtra, India | Tel No: +91 9920923338 | Contact Person: Reshma Susan, Company Secretary and Compliance Officer

PROMOTERS OF OUR COMPANY: PAULSON PAUL THAZHATHEDATH AND HANS ALBERT LEWIS

THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE LIMITED ("NSE EMERGE")
Our Company has filed the Prospectus dated January 18, 2024 with the RoC and trading of the Equity Shares Allotted pursuant to the Issue is expected to commence on February 02, 2024.

BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF 8,49,600 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF DOCMODE HEALTH TECHNOLOGIES LIMITED ("THE COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹79/- PER EQUITY SHARE (THE "ISSUE PRICE"), (INCLUDING A PREMIUM OF ₹ 69/- PER EQUITY SHARE), AGGREGATING ₹ 671.184 LAKHS ("THE ISSUE"), OF WHICH 43,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- FOR CASH AT A PRICE OF ₹79/- EACH AGGREGATING ₹34.12 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 8,06,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/ EACH FOR CASH AT A PRICE OF ₹79/- PER EQUITY SHARE, AGGREGATING TO ₹ 637.05 LAKHS IS HERE IN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 27.03 % AND 25.66% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF THE COMPANY. FOR FURTHER DETAILS, PLEASE REFER TO CHAPTER TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE NO 239 OF THE PROSPECTUS.

RISKS TO INVESTORS

1. We are dependent on our relationships with healthcare professionals, and our business and financial results could be to an extent impacted if we are not able to engage such healthcare professionals on a regular basis.

2. Our ability to retain the present number of learners and professionals serviced by us and attract new learners and professionals is dependent upon various factors including our reputation and our ability to maintain a high level of service quality. Any failure by us to retain or attract learners and professionals may impact our business and its revenues.

3. Our Company is yet to place orders for the purchase of IT infrastructure and operating system. Any delay in placing orders or procurement of such machinery may delay the schedule of implementation

4. The business in which we operate is specifically regulated. The central and state governments may change the existing regulations or introduce a new regulatory framework in the future. The impact of such changes or new regulations on the business cannot be ascertained presently and may affect our business adversely in the future.

5. Our success depends significantly on our ability to continue to innovate and implement technological advances. If we are unable to keep pace with evolving technology and user preferences, our business, results of operations and prospects may be adversely affected.

6. There have been some instances of delay/ default in payment of statutory dues by our Company in the past.

7. Strong competition in the business of providing professional medical learning could also decrease our market share and compel us to reduce course fees or provide higher discounts on our course fees. This may have a material adverse impact on the number of learners and health care professionals enrolled with us, revenues and profitability.

8. Any disruption in our information technology systems may adversely affect our business, results of operations and prospects.
9. WEIGHTED AVERAGE PRICE AT WHICH THE EQUITY SHARES WERE ACQUIRED BY OUR PROMOTERS IN THE ONE YEAR PRECEDING THE DATE OF THE PROSPECTUS
The weighted average price at which the equity shares were acquired by our Promoters in the one year preceding the date of the Prospectus.

Name	Number of Shares	Weighted Average Cost of Acquisition per Equity Share (in Rs.)*
Paulson Paul Thazhathedath	335790	Nil
Hans Albert Lewis	335790	Nil

*As certified by R Sundaresan Aiyar & Co, Chartered Accountants, pursuant to their certificate dated January 18, 2024

10. AVERAGE COST OF ACQUISITION
The average cost of acquisition per Equity Share to our Promoters as at the date of the Prospectus is:

Name	Number of Shares	Average Cost of Acquisition per Equity Share (in Rs.)
Paulson Paul Thazhathedath	7,45,290	0.65
Hans Albert Lewis	7,45,290	0.65

*As certified by R Sundaresan Aiyar & Co, Chartered Accountants, pursuant to their certificate dated January 18, 2024.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10.00/- EACH AND
THE ISSUE PRICE IS ₹79 PER EQUITY SHARE
THE ISSUE PRICE IS 7.9 TIMES OF THE FACE VALUE OF THE EQUITY SHARES

ISSUE OPENED ON: January 25, 2024

ISSUE CLOSED ON: January 29, 2024

PROPOSED LISTING

The Equity Shares of the Company offered through the Prospectus dated January 18, 2024 are proposed to be listed on the NSE Emerge in terms of the Chapter IX of SEBI (ICDR) Regulations, 2018 as amended from time to time. Our Company has received In-Principle Approval Letter dated August 22, 2023 from NSE Limited for listing our shares and also for using its name in the Issue document for listing of our shares on NSE Emerge. It is to be distinctly understood that the permission given by NSE Limited should not in any way be deemed or construed that the Issue Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Issue Document. The investors are advised to refer to the Prospectus for the full text of the "Disclaimer Clause of the Emerge Platform of NSE Limited" on page 230 of the Prospectus. For the purpose of this issue the Designated Stock Exchange will be NSE Emerge. The trading is proposed to be commenced on February 02, 2024 (Subject to receipt of listing and trading approval from NSE Limited).

This issue is being made through Fixed Price Process in terms of Chapter IX of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI (ICDR) Regulations") as amended and Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR"). According to Regulation 25(2) of the SEBI (ICDR) Regulations, 2018 as amended from time to time, the allocation in the Net Issue to the Public category is made as follows: (a) minimum 50% of the net issue of shares shall be allocated to Retail Individual Investors and (b) remaining to: (i) Individual applicants other than retail individual investors; and (ii) other investors including corporate bodies or institutions, irrespective of number of specified securities applied for; provided that the unsubscribed portion in either of categories specified in clauses (a) or (b) may be allocated to applicants in the other category.

If the retail individual investor category is entitled to more than allocated portion on proportionate basis, accordingly the retail individual investors shall be allocated that higher percentage. For further details, please refer to chapter titled "Issue Structure" beginning on page no. 250 of the Prospectus.

All investors have participated in this issue through Application Supported by Blocked Amount ("ASBA") process including through Unified Payment Interface ("UPI") mode (as applicable) by providing the details of the respective bank accounts / UPI ID as applicable in which the corresponding application amounts were blocked by Self Certified Syndicate Banks (the "SCSBs") / Sponsor Bank as the case may be.

SUBSCRIPTION DETAILS

DETAILS OF THE APPLICATION:

The issue was subscribed to the extent of 243.62 times as per the bid books of NSE (the "Bid Files") after removing multiple and duplicate bids.

The details of the applications received in the Issue from Retail Individual Investors, Non-Institutional Investors and Market Maker (before and after technical rejections & withdrawal) are as follows:

DETAILS OF APPLICATIONS RECEIVED (before technical rejection)

Category	Number of applications	Number of equity shares Bid for	Number of equity shares reserved as per Prospectus	Number of times subscribed
Market Maker	1	43,200	43,200	1.00
Non - Retail Individual Investor's	7,707	7,85,85,600	4,03,200	194.90
Retail Individual Investor's	58,072	9,29,15,200	4,03,200	230.44
TOTAL	65,780	17,15,44,000	8,49,600	201.91

DETAILS OF VALID APPLICATIONS:

Sr. No.	Category	Gross		Less: Rejections*		Valid	
		Applications	Equity Shares	Applications	Equity Shares	Applications	Equity Shares
1	Market Maker	1	43,200	-	-	1	43,200
2	Non-Retail Investors	7,707	7,85,85,600	91	4,08,000	7,616	7,81,77,600
3	Retail Individual Investors	58,072	9,29,15,200	908	14,52,800	57,164	9,14,62,400
	Total	65,780	17,15,44,000	999	18,60,800	64,781	16,96,83,200

* This includes 17 applications for 27,200 equity shares from Retail investors which were not in book but excludes bids (UPI mandates) not accepted by investors.

A. ALLOCATION: The Basis of Allotment was finalized in consultation with the Designated Stock Exchange i.e NSE Limited on January 31, 2024 .

B. Allocation to Market Maker (After Technical Rejections): The Basis of Allotment to the Market Maker, at the issue price of ₹79/- per Equity Share, was finalised in consultation with NSE Emerge. The category was subscribed by 1 time. The total number of shares allotted in this category is 43,200 Equity shares in full out of reserved portion of 43,200 Equity Shares.

C. Allocation to Retail Individual Investors (After Technical Rejections): The Basis of Allotment to the Retail Individual Investors, at the issue price of ₹79/- per Equity Share, was finalized in consultation with NSE Emerge. The category was subscribed by 226.84 times. The total number of shares allotted in this category is 4,35,200 Equity shares out of reserved portion of 4,03,200 Equity Shares.

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Allocation per Applicant		Ration of allottees to applicants	Number of successful applicants (after rounding)	% to total	Total No. of shares allocated/allotted	% to total
							Before Rounding off	After Rounding off					
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13)	(14)
1	1,600	57,164	100.00	9,14,62,400	100.00	4,35,200	7.61	1,600	1 210	272	100.00	4,35,200	100.00
GRAND TOTAL		57,164	100.00	9,14,62,400	100.00	4,35,200				272	100.00	4,35,200	100.00

D. Allocation to Non-Retail Individual Investors (After Technical Rejections): The Basis of Allotment to the Non-Retail Individual Investors, at the issue price of ₹79/- per Equity Share, was finalized in consultation with NSE Limited. The category was subscribed by 193.89 times. The total number of shares allotted in this category is 3,71,200 Equity shares out of reserved portion of 4,03,200 Equity Shares.

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Allocation per Applicant		Ration of allottees to applicants	Number of successful applicants (after rounding)	% to total	Total No. of shares allocated/allotted	% to total	
							Before Rounding off	After Rounding off						
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13)	(14)	
1	3200	5133	67.40	16425600	21.01	77991	15.19	1600	4	419	49	23.56	78400	21.14
2	4800	602	7.91	2889600	3.70	13720	22.79	1600	9	602	9	4.33	14400	3.88
3	6400	253	3.32	1619200	2.07	7688	30.39	1600	5	253	5	2.40	8000	2.16
4	8000	179	2.35	1432000	1.83	6799	37.98	1600	4	179	4	1.92	6400	1.72
5	9600	97	1.27	931200	1.19	4422	45.58	1600	3	97	3	1.44	4800	1.29
6	11200	155	2.04	1736000	2.22	8243	53.18	1600	1	31	5	2.40	8000	2.16
7	12800	497	6.53	6361600	8.14	30206	60.78	1600	19	497	19	9.14	30400	8.20
8	14400	124	1.63	1785600	2.28	8478	68.37	1600	5	124	5	2.40	8000	2.16
9	16000	153	2.01	2448000	3.13	11624	75.97	1600	7	153	7	3.37	11200	3.02
10	17600	24	0.32	422400	0.54	2006	83.58	1600	1	24	1	0.48	1600	0.43
11	19200	38	0.50	729600	0.93	3464	91.16	1600	1	19	2	0.96	3200	0.86
12	20800	10	0.13	208000	0.27	988	98.8	1600	1	10	1	0.48	1600	0.43
13	22400	15	0.20	336000	0.43	1595	106.33	1600	1	15	1	0.48	1600	0.43
14	24000	32	0.42	768000	0.98	3647	113.97	1600	1	16	2	0.96	3200	0.86
15	25600	20	0.26	512000	0.65	2431	121.55	1600	1	20	1	0.96	1600	0.43
16	27200	5	0.07	136000	0.17	646	129.2	1600	0	0	0	0.00	0	0.00
17	28800	25	0.33	720000	0.92	3419	136.76	1600	2	25	2	0.96	3200	0.86
18	30400	3	0.04	91200	0.12	433	144.33	1600	0	0	0	0.00	0	0.00
19	32000	35	0.46	1120000	1.43	5318	151.94	1600	3	35	3	1.44	4800	1.29
20	33600	7	0.09	235200	0.30	1117	159.57	1600	1	7	1	0.48	1600	0.43
21	35200	5	0.07	176000	0.23	836	167.2	1600	0	0	0	0.48	0	0.00
22	36800	4	0.05	147200	0.19	699	174.75	1600	0	0	0	0.00	0	0.00
23	38400	7	0.09	268800	0.34	1276	182.29	1600	1	7	1	0.48	1600	0.43
24	40000	7	0.09	280000	0.36	1330	189.86	1600	1	7	1	0.48	1600	0.43
25	43200	4	0.05	172800	0.22	820	205	1600	0	0	0	0.48	0	0.00
26	44800	2	0.03	89600	0.11	425	212.5	1600	0	0	0	0.00	0	0.00
27	46400	2	0.03	92800	0.12	441	220.5	1600	0	0	0	0.00	0	0.00
28	48000	11	0.14	528000	0.68	2507	227.91	1600	2	11	2	0.96	3200	0.86
29	49600	1	0.01	49600	0.06	236	236	1600	0	0	0	0.00	0	0.00
30	51200	2	0.03	102400	0.13	486	243	1600	0	0	0	0.00	0	0.00
31	52800	1	0.01	52800	0.07	251	251	1600	0	0	0	0.00	0	0.00
32	54400	5	0.07	272000	0.35	1292	258.4	1600	1	5	1	0.48	1600	0.43
33	56000	4	0.05	224000	0.29	1064	266	1600	1	4	1	0.48	1600	0.43
34	57600	1	0.01	57600	0.07	274	273	1600	0	0	0	0.00	0	0.00
35	59200	2	0.03	118400	0.15	562	281	1600	0	0	0	0.00	0	0.00
36	62400	4	0.05	249600	0.32	1185	296.25	1600	1	4	1	0.48	1600	0.43
37	64000	9	0.12	576000	0.74	2735	303.89	1600	2	9	2	0.96	3200	0.86
38	65600	3	0.04	196800	0.25	934	311.33	1600	1	3	1	0.48	1600	0.43
39	70400	2	0.03	140800	0.18	669	334.5	1600	0	0	0	0.00	0	0.00
40	72000	5	0.07	360000	0.46	1709	341.8	1600	1	5	1	0.48	1600	0.43

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Allocation per Applicant		Ration of allottees to applicants	Number of successful applicants (after rounding)	% to total	Total No. of shares allocated/allotted	% to total	
							Before Rounding off	After Rounding off						
41	73600	1	0.01	73600	0.09	349	349	1600	0	0	0	0.00	0	0.00
42	75200	2	0.03	150400	0.19	714	357	1600	0	0	0	0.00	0	0.00
43	78400	3	0.04	235200	0.30	1117	372.33	1600	1	3	1	0.48	1600	0.43
44	80000	5	0.07	400000	0.51	1899	379.8	1600	1	5	1	0.48	1600	0.43
45	81600	3	0.04	244800	0.31	1162	387.33	1600	1	3	1	0.48	1600	0.43
46	83200	2	0.03	166400	0.21	790	395	1600	0	0	0	0.00	0	0.00
47	84800	3	0.04	254400	0.33	1208	402.67	1600	1	3	1	0.48	1600	0.43
48	88000	3	0.04	264000	0.34	1255	418	1600	1	3	1	0.48	1600	0.43
49	94400	3	0.04	283200	0.36	1345	448.33	1600	1	3	1	0.48	1600	0.43
50	96000	2	0.03	192000	0.25	912	456	1600	1	2	1	0.48	1600	0.43
51	100800	8	0.11	806400	1.03	3829	478.63	1600	1	4	2	0.96	3200	0.86
52	104000	3	0.04	312000	0.40	1481	493.67	1600	1	3	1	0.48	1600	0.43
53	110400	2	0.03	220800	0.28	1048	524	1600	1	2	1	0.48	1600	0.43
54	115200	1	0.01	115200	0.15	547	547	1600	0	0	0	0.00	0	0.00
55	116800	2	0.03	233600	0.30	1109	554.5	1600	1	2	1	0.48	1600	0.43
56	120000	1	0.01	120000	0.15	570	570	1600	0	0	0	0.00	0	0.00
57	121600	1	0.01	121600	0.16	577	577	1600	0	0	0	0.00	0	0.00
58	124800	1	0.01	124800	0.16	593	593	1600	0	0	0	0.00	0	0.00
59	126400	6	0.08	758400	0.97	3601	600.17	1600	1	3	2	0.96	3200	0.86
60	128000	3	0.04	384000	0.49	1823	607.67	1600	1	3	1	0.48	1600	0.43
61	131200	1	0.01	131200	0.17	623	623	1600	0	0	0	0.00	0	0.00
62	132800	2	0.03	265600	0.34	1261	630.5	1600	1	2	1	0.48	1600	0.43
63	137600	1	0.01	137600	0.18	653	653	1600	0	0	0	0.00	0	0.00
64	139200	2	0.03	278400	0.36	1322	661	1600	1	2	1	0.48	1600	0.43
65	142400	3	0.04	427200	0.55	2028	676	1600	1	3	1	0.48	1600	0.43
66	145600	1	0.01	145600	0.19	691	691	1600	0	0	0	0.00	0	0.00
67	153600	1	0.01	153600	0.20	729	729	1600	0	0	0	0.00	0	0.00
68	155200	2	0.03	310400	0.40	1474	737	1600	1	2	1	0.48	1600	0.43
69	160000	2	0.03	320000	0.41	1519	759.5	1600	1	2	1	0.48	1600	0.43
70	161600	1	0.01	161600	0.21	767	767	1600	0	0	0	0.00	0	0.00
71	163200	2	0.03	326400	0.42	1550	775	1600	1	2	1	0.48	1600	0.43
72	164800	1	0.01	164800	0.21	783	782	1600	0	0	0	0.00	0	0.00
73	169600	1	0.01	169600	0.22	805	805	1600	0	0	0	0.48	0	0.00
74	180800	1	0.01	180800	0.23	858	858	1600	0	0	0	0.48	0	0.00
75	184000	1	0.01	184000	0.24	874	874	1600	1	1	1	0.48	1600	0.43
76	187200	1	0.01	187200	0.24	889	889	1600	1	1	1	0.48	1600	0.43
77	188800	1	0.01	188800	0.24	896	896	1600	1	1	1	0.48	1600	0.43
78	196800	1	0.01	196800	0.25	934	934	1600	1	1	1	0.48	1600	0.43
79	198400	1	0.01	198400	0.25	942	942	1600	1	1	1	0.48	1600	0.43
80	203200	2	0.03	406400	0.52	1930	965	1600	1	2	1	0.48	1600	0.43
81	206400	1	0.01	206400	0.26	980	980	1600	1	1	1	0.48	1600	0.43
82	208000	1	0.01	208000	0.27	988	988	1600	1	1	1	0.48	1600	0.43
83	211200	1	0.01	211200	0.27	1003	1003	1600	1	1	1	0.48	1600	0.43
84	217600	1	0.01	217600	0.28	1033	1033	1600	1	1	1	0.48	1600	0.43
85	220800	1	0.01	220800	0.28	1048	1048	1600	1	1	1	0.48	1600	0.43
86	222400	1	0.01	222400	0.28	1056	1056	1600	1	1	1	0.48	1600	0.43
87	225600	1	0.01	225600	0.29	1071	1071	1600	1	1	1	0.48	1600	0.43
88	232000	1	0.01	232000	0.30	1102	1102	1600	1	1	1	0.48	1600	0.43
89	240000	1	0.01	240000	0.31	1140	1140	1600	1	1	1	0.48	1600	0.43
90	252800	1	0.01	252800	0.32	1200	1200	1600	1	1	1	0.48	1600	0.43
91	260800	1	0.01	260800	0.33	1238	1238	1600	1	1	1	0.48	1600	0.43
92	265600	1	0.01	265600	0.34	1261	1261	1600	1	1	1	0.48	1600	0.43
93	307200	1	0.01	307200	0.39	1459	1459	1600	1	1	1	0.48	1600	0.43
94	313600	1	0.01	313600	0.40	1489	1489	1600	1	1	1	0.48	1600	0.43
95	320000	1	0.01	320000	0.41	1519	1519	1600	1	1	1	0.48	1600	0.43
96	321600	1	0.01	321600	0.41	1527	1527	1600	1	1	1	0.48	1600	0.43
97	334400	1	0.01	334400	0.43	1588	1588	1600	1	1	1	0.48	1600	0.43
98	340800	1	0.01	340800	0.44	1618	1618	1600	1	1	1	0.48	1600	0.43
99	352000	1	0.01	352000	0.45	1671	1671	1600	1	1	1	0.48	1600	0.43
100	390400	1	0.01	390400	0.50	1854	1854	1600	1	1	1	0.48	1600	0.43
101	392000	1	0.01	392000	0.50	1861	1861	1600	1	1	1	0.48	1600	0.43
102	438400	1	0.01	438400	0.56	2082	2082	1600	1	1	1	0.48	1600	0.43
103	520000	1	0.01	520000	0.67	2469	2469	3200	1	1	1	0.48	3200	0.86
104	544000	1	0.01	544000	0.70	2583	2583	3200	1	1	1	0.48	3200	0.86
105	560000	1	0.01	560000	0.72	2659	2659	3200	1	1	1	0.48	3200	0.86
106	561600	1	0.01	561600	0.72	2667	2667	3200	1	1	1	0.48	3200	0.86
107	569600	1	0.01	569600	0.73	2705	2705	3200	1	1	1	0.48	3200	0.86
108	571200	1	0.01	571200	0.73	2712	2712	3200	1	1	1	0.48	3200	0.86
109	662400	1	0.01	662400	0.85	3145	3145	3200	1	1	1	0.48	3200	0.86
110	761600	1	0.01	761600	0.97	3616	3616	3200	1	1	1	0.48	3200	0.86
111	806400	15	0.20	12096000	15.47	57434	3828.93	3200	1	1	15	7.21	48000	12.94
			0.00		0.00			1600	2	5		0.00	9600	2.59
GRAND TOTAL	7,616	100.00	7,81,77,600	100.00	3,71,201					203	100.00	3,71,200	100.00	

Continued from previous page

The Board of Directors of the Company at its meeting held on January 31, 2024 has taken on record the Basis of Allotment of Equity Shares, as approved by the Designated Stock Exchange viz. NSE Emerge and has authorized the online corporate action for the allotment of the Equity Shares in dematerialised form to various successful applicants. The CAN-cum-Refund Orders and Allotment Advice and/or Notices are being dispatched to the address of the applicants as registered with the depositories / as filled in the application form on February 01, 2024. Further, the instructions to Self-Certified Syndicate Banks being processed on January 31, 2024 for unblocking fund. In case the same is not received in compliance with the applicable timeline, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The company shall file the listing application with NSE Limited on or before February 01, 2024. The Company is in process of obtaining the listing & the trading approval from NSE Limited and the trading is expected to commence on February 02, 2024.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as Ascribed to them in the Prospectus dated January 18, 2024.

DISCLOSURES PERTAINING TO THE LM'S TRACK RECORD ON PAST ISSUES WITH A BREAKUP OF HANDLING OF SME IPOs FOR THE LAST 3 YEARS:
FEDEX SECURITIES PRIVATE LIMITED

TYPE	FY 2020-21	FY 2021-22	FY 2022-23
SME IPO	2	5	7
MAIN BOARD	0	0	0

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, **Bigshare Services Private Limited** at ipo@bigshareonline.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the first/ sole applicants, serial number of the application form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:



BIGSHARE SERVICES PRIVATE LIMITED
Office No. S6 - 2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Cave Road, Andheri - [East], Mumbai - 400093, Maharashtra, India.
Tel No: +91 22 6263 8200
Fax No: +91 22 6263 8299
E-mail Id: ipo@bigshareonline.com
Website: www.bigshareonline.com
Contact Person: Mr. Aniket Chindarkar
SEBI Registration No: INR000001385



LEAD MANAGER TO THE ISSUE

FEDEX SECURITIES PRIVATE LIMITED

B 7, 3rd Floor, Jay Chambers, Dayaldas Road, Vile Parle (East), Mumbai - 400 057, Maharashtra, India
Telephone +91 81049 85249

E-mail: mb@fedsec.in

Investor Grievance E-Mail: mb@fedsec.in

Website: www.fedsec.in

Contact Person: Mr. Saipan Sanghvi

SEBI Registration Number: INM000010163

Date: January 31, 2024

Place: Mumbai, Maharashtra

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF DOCMODE HEALTH TECHNOLOGIES LIMITED.

The Prospectus is available on the website of SEBI at www.sebi.gov.in, the website of the Lead Manager at www.fedsec.in, website of the National Stock Exchange of India Limited at www.nseindia.com and website of Issuer Company at www.docmode.org For details, investors should refer to and rely on the Prospectus including the section titled **"Risk Factors"** beginning on page 27 of the Prospectus.

The Equity Shares offered in this Issue have not been and will not be registered under the US Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

INVIGORATED BUSINESS CONSULTING LIMITED
(Formerly Escorts Finance Limited)

CIN: L74110CH1987PLC033652

Regd. Office: Plot No. 19, Industrial Area, Phase 2, Chandigarh - 160002

Phone: 0129-2564116, E-mail: escortsfinance@escortsfinance.com, Website: www.escortsfinance.com

EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023
Rs. In Lakhs

Sl. No.	Particulars	Quarter ended	Nine Months ended	Quarter ended
		31.12.2023	31.12.2023	31.12.2022
		(Unaudited)	(Unaudited)	(Unaudited)
1	Total Income from Operations	9.97	21.20	4.59
2	Net Profit/ (loss) for the period (Before Tax, Exceptional and/ or Extraordinary Items)	0.45	(12.42)	(7.94)
3	Net Profit/ (loss) for the period before Tax (After Exceptional and/ or Extraordinary Items)	0.45	(12.42)	(7.94)
4	Net Profit/ (loss) for the period after Tax (After Exceptional and/ or Extraordinary Items)	0.45	(12.42)	(7.94)
5	Total Comprehensive Income for the period (Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)	0.45	(12.42)	(7.94)
6	Paid-up Equity Share Capital (Face Value of Rs.10/- each)	4,017.25	4,017.25	4,017.25
7	Other Equity (Excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	-	-	-
8	Earnings Per Share (of Rs.10/- each) for the period (not annualised): Basic & Diluted (Rs.)	0.0011	(0.0309)	(0.0198)

Notes:-

- The turnover/ income is NIL post name change and business activities.
- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly & Year to date Financial Results are available on the Stock Exchange website www.bseindia.com and on the Company's website www.escortsfinance.com

By Order of the Board
For Invigorated Business Consulting Limited
Kamal Sachdeva
Director
DIN: 10364431

Place: Faridabad
Date: January 31, 2024



MANKIND PHARMA LIMITED

Registered Office: 208, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; **Tel.:** +91 11 4747 6600

Corporate Office: 262, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; **Tel.:** +91 11 4684 6700

Email: investors@mankindpharma.com, **Website:** www.mankindpharma.com, **CIN:** L74899DL1991PLC044843

Extract of unaudited financial results for the quarter and nine months ended December 31, 2023

(₹ in Lacs except as stated otherwise)

S. No.	Particulars	Consolidated				
		For the quarter ended			For the nine months ended	
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Audited)
1	Revenue from operations	260,695.89	270,809.90	209,093.03	789,367.54	669,676.60
2	Profit for the period/year before tax	56,232.92	64,098.71	37,898.93	182,778.18	129,395.38
3	Profit for the period/year after tax	45,981.37	51,117.67	29,571.95	146,517.88	101,597.76
4	Total comprehensive income for the period/ year	46,556.60	50,905.98	29,382.74	146,551.79	101,019.09
5	Paid-up equity share capital	N.A.	N.A.	N.A.	N.A.	N.A.
6	Other equity excluding revaluation reserve	N.A.	N.A.	N.A.	N.A.	N.A.
7	Earnings per equity share of face value of ₹ 1/- each	11.33	12.51	7.09	35.99	24.87
	- Basic EPS (in ₹)	11.31	12.49	7.09	35.94	24.87
	- Diluted EPS (in ₹)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)

The key standalone financial information is as under:

(₹ in Lacs except as stated otherwise)

S. No.	Particulars	For the quarter ended			For the nine months ended		For the Year ended 31.03.2023 (Audited)
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Audited)	
1	Revenue from operations	235,856.62	245,334.52	193,623.10	711,212.27	625,503.15	812,715.32
2	Profit for the period/year before tax	57,635.16	61,196.24	32,563.69	171,470.71	120,740.31	156,283.66
3	Profit for the period/year after tax	48,707.33	47,288.44	24,887.32	136,923.99	96,727.00	124,825.80
4	Total comprehensive income for the period/year	49,399.98	46,932.51	24,606.02	136,991.74	95,870.94	124,339.91

Notes:

- The above is an extract of the detailed format of Quarterly Unaudited Consolidated and Standalone Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.mankindpharma.com.
- The Unaudited Consolidated and Standalone Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on January 31, 2024.

For and on behalf of
MANKIND PHARMA LIMITED

Sd/-
Ramesh Juneja
Chairman and Whole Time Director
DIN: 00283399

Place: New Delhi
Date: January 31, 2024

सीआईएन : L74130DL1985PLC021532
पंजीकृत कार्यालय : 122, अमरा तवर, विलेपार्ले, काजल नगर चर्च 11, नई दिल्ली-110024
ईमेल आईडी : grovyindia@gmail.com, वेबसाइट : www.grovyindia.com दूरभाष नं: 011-46740000

31 दिसंबर 2023 को समाप्त (तमाह) एवं तिमाह के अलखपराखित एकादशताय पाएषामा का साखस

क्र. सं.	विवरण	31.12.2023 को समाप्त होखती तिमाह	31.12.2023 को समाप्त ती माह	31.12.2022 को समाप्त तत्पुर्वकी तिमाह	31.03.2023 को समाप्त पूर्वकी वर्ष
1	परिचालनी से कुल आय	608.41	1638.75	337.17	2117.43
2	अवधि हेतु निवल लाम/ (हानि) (कर, आप्यादिक एवं/ अय्या असाधारण मदो से पूर्व)	19.34	126.80	47.46	121.99
3	कर पूर्व अवधि हेतु निवल लाम/ (हानि) (आप्यादिक एवं/ अय्या असाधारण मदो के उपरान्त)	19.34	126.80	47.46	121.99
4	कर परखान्त अवधि हेतु निवल लाम/ (हानि) (आप्यादिक एवं/ अय्या असाधारण मदो के उपरान्त)	16.54	96.1	34.84	90.52
5	अवधि हेतु कुल व्यापक आय (अवधि हेतु लाम/ (हानि) (कर उपरान्त) तथा अन्य व्यापक आय (कर उपरान्त) से समाविष्ट)	22.04	121.22	44.49	90.92
6	समाप्त अलग पूंजी	333.41	333.41	333.41	333.41
7	आरक्षितिया (पुनर्मुल्यांकन आरक्षित छोडकर) पूर्वकी वर्ष के लेखापरोक्षित तुलन-पत्र में निदर्शितनुसार				1426.04
8	अप्य प्रति अक्ष (रु: 10/- प्रत्येक का)	0.5	2.88	1.04	2.72

टिप्पणिया :

- उपरोक्त साखस, सेबी (सूचीकरण दायित्व एवं अन्य प्रकटीकरण आवश्यकताएं) विनियमावली 2015 के विनियम 33 के अंतर्गत स्टॉक एक्सचेंज के पास फाइलबद्ध विस्तृत त्रैमासिक वित्तीय परिणामों का एक साखस है। विस्तृत त्रैमासिक वित्तीय परिणाम, स्टॉक एक्सचेंज की वेबसाइट अर्थात (www.bseindia.com) और कंपनी की वेबसाइट अर्थात (www.grovyindia.com) पर उपलब्ध है।
- उपरोक्त अलेखापरोक्षित वित्तीय परिणामों तथा खण्डवार परिणामों की समीक्षा एवं संस्तुति, लेखापरिक्षण समिति द्वारा 31-01-2024 को आयोजित अपनी बैठक में की गयी है तथा निदेशक मंडल द्वारा 31-01-2024 को आयोजित अपनी बैठक में इनका अनुमोदन किया गया है।

स्थान : नई दिल्ली
दिनांक : 31-01-2024

कृते श्री डी इंडिया लिमिटेड
हस्ता/-
प्रकाश चंद जालान
अध्यक्ष
डीआईएन : 00475656

Criminal Court, Ludhiana
In The Court Of Ms. Shaweta JMJC
Ludhiana COMA/ 26678/2019
CNR NO: PBLD03-032587-2019
Peshi: 29-02-2024
publication notice for proclamation under section 82 CR.PC Compliant R/w sec- 136 of n.i.act
M/s D Marketing
Vs.
M/s Punjab Machine Tools Corporation
Notice To: Sajid Rehman, Prop Of M/s Punjab Machine Tools Corporation
Exhibition Road Corner, Patna Bihar (M: 06202324535)
Whereas it has been proved to the satisfaction of this court that you the accused above named cannot be served in the ordinary way of service. Hence this proclamation under section 82 CRPC is hereby issued against you with a direction that you should appear personally before this court on 29-02-2024 at 10:00 a.m. or within 30 days from the date of publication of this proclamation take notice that, in default of your part to appear as directed above the above said case will be heard and determined as per law, in your absence Given under my hand and the seal of the court, for details login to: https://highcourthcd.gov.in/trs=district_n_office&district=ludhiana JMJC Ludhiana

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR UNITS OR SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT

(Please scan this QR Code to view the Notice)

JNK INDIA LIMITED

Our Company was incorporated as "JNK India Private Limited", a private limited company under the Companies Act, 1956 in Thane, Maharashtra, pursuant to a certificate of incorporation dated June 14, 2010, granted by the Registrar of Companies, Maharashtra at Mumbai ("RoC"). Pursuant to the conversion of our Company from a private limited company into a public limited company and as approved by our Board on April 12, 2023, and a special resolution passed by our Shareholders at the EGM on April 14, 2023, the name of our Company was changed to "JNK India Limited", and the RoC issued a fresh certificate of incorporation on May 26, 2023. For details of change in the Registered Office, see **"History and Certain Corporate Matters - Changes in the Registered Office"** on page 180 of the DRHP.

Registered and Corporate Office: Unit No. 203, 204, 205 & 206, Opposite TMC Office Centrum IT Park, Near Satkar Hotel, Thane -West, Thane 400 604, Maharashtra, India
Tel: +91 22 6885 8000; **Contact Person:** Ashish Soni, Company Secretary and Compliance Officer; **Tel:** + 91 22 6885 8000; **E-mail:** compliance@jnkindia.com; **Website:** www.jnkindia.com; **Corporate Identity Number:** U29268MH2010PLC204223

NOTICE TO INVESTORS ("NOTICE")

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH ("EQUITY SHARES") OF JNK INDIA LIMITED ("OUR COMPANY") OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER"), COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 3,000.00 MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 8,421,052 EQUITY SHARES (THE "OFFERED SHARES") AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER FOR SALE"). THE OFFER WILL CONSTITUTE [●] % OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL.

Potential Bidders may note the following:

- On November 30, 2023, one of our Promoters, Dipak Kacharulal Bharuka transferred 4,960,000 Equity Shares to Bharuka Family Private Trust ("Trust"), a family private trust managed by Amicorp Trustees India Private Limited as its trustee ("Trustee") established vide a trust deed executed on February 22, 2023 ("Trust Deed"), wherein Dipak Kacharulal Bharuka and his wife Priya Bharuka are the primary beneficiaries, by way of a gift, for no consideration ("Transfer"). Except for Dipak Kacharulal Bharuka, one of our Promoters, Directors and Key Managerial Personnel and Priya Bharuka, one of the members of the Promoter Group of Dipak Kacharulal Bharuka, the Trust is not connected with our Company, our Promoters, our Promoter Group, our Directors, our Key Managerial Personnel, our Subsidiaries, our Group Companies and their respective directors and key managerial personnel.
- Further, on January 30, 2024, the Trust transferred 4,960,000 Equity Shares to one of our Promoters, Dipak Kacharulal Bharuka, by way of a gift, for no consideration ("Reverse Transfer").

The details of Transfer and Reverse Transfer are provided below:

Date of Transaction/ Transfer	Name of Transferor	Name of Transferee/ Acquirer/Allottee	Nature of Transfer	Number of Equity Shares Transferred	Transfer Price per Equity Shares (in ₹)
November 30, 2023	Dipak Kacharulal Bharuka	Bharuka Family Private Trust managed by Amicorp Trustees India Private Limited	Gift	4,960,000	Nil
January 30, 2024	Bharuka Family Private Trust managed by Amicorp Trustees India Private Limited	Dipak Kacharulal Bharuka	Gift	4,960,000	Nil

Details of the shareholding of the Trust and Dipak Kacharulal Bharuka set forth below:

- Shareholding of Dipak Kacharulal Bharuka and the Trust in the Company, prior to and subsequent to the Transfer-

S. No.	Date of Transaction /Transfer	Name	No. of Equity Shares	Percentage of pre-Offer share capital of the Company (%)	No. of Equity Shares	Percentage of pre-Offer share capital of the Company (%)
I.	November 30, 2023	Dipak Kacharulal Bharuka	4,960,000	10.25	-	-
		Bharuka Family Private Trust managed by Amicorp Trustees India Private Limited	-	-	4,960,000	10.25

- Shareholding of the Trust and Dipak Kacharulal Bharuka in the Company, prior to and subsequent to the Reverse Transfer-

S. No.	Date of Transaction /Transfer	Name	No. of Equity Shares	Percentage of pre-Offer share capital of the Company (%)	No. of Equity Shares	Percentage of pre-Offer share capital of the Company (%)
1.	January 30, 2024	Bharuka Family Private Trust managed by Amicorp Trustees India Private Limited	4,960,000	10.25	-	-
		Dipak Kacharulal Bharuka	-	-	4,960,000	10.25

IIFL SECURITIES

IIFL Securities Limited
24th Floor, One Lodha Place
Senapati Bapat Marg, Lower Panel (West),
Mumbai 400 013 Maharashtra, India
Tel: +91 22 4646 4728
E-mail: jnk.ipo@iiflcap.com
Investor grievance e-mail: customercare@iicisecurities.com
Website: www.iiflcap.com
Contact person: Mukesh Garg/ Pawan Jain
SEBI registration no.: INM000010940

ICICI Securities Limited
ICICI Venture House, Appasaheb Marathe Marg,
Prabhadevi, Mumbai 400 025 Maharashtra, India
Tel: +91 22 6807 7100
E-mail: jnk.ipo@icicisecurities.com
Investor grievance e-mail: customercare@icicisecurities.com
Website: www.icicisecurities.com
Contact person: Namrata Ravasia/ Harsh Thakkar
SEBI registration no.: INM000011179

LINK Intime

Link Intime India Private Limited
C-101, 1st Floor, 247 Park, L.B.S. Marg,
Vikhroli West, Mumbai 400 083 Maharashtra, India
Tel: +91 810 811 4949
E-mail: jnkindia.ipo@linkintime.co.in
Website: www.linkintime.co.in
Investor grievance e-mail: jnkindia.ipo@linkintime.co.in
Contact person: Shanti Gopalkrishnan
SEBI Registration No.: INR000004058

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **JNK INDIA LIMITED**
Sd/-
Ashish Soni
Company Secretary and Compliance Officer

Place : Mumbai, Maharashtra
Date : January 31, 2024

JNK India Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed the DRHP with the Securities and Exchange Board of India ("SEBI") and the Stock Exchanges. The DRHP is available on the websites of the Company at www.jnkindia.com, SEBI at www.sebi.gov.in, the book running lead managers, IIFL Securities Limited and ICICI Securities Limited at <https://www.iiflcap.com> and <https://www.icicisecurities.com>, respectively, and National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see **"Risk Factors"** of the DRHP on page 28, when available. Potential investors should not rely on the DRHP filed with SEBI for any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the United States Securities Act of 1933, as amended (the **"U.S. Securities Act"**) or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made.

CONCEPT

www.readwhere.com

Chandigarh